HLS Therapeutics Inc. announced that it has successfully entered into a Product Listing Agreement with the Quebec Minister of Health and Social Services, for the listing and public reimbursement of Vascepa (icosapent ethyl) on the Public Prescription Drug Insurance Plan of the Régime de l'Assurance Maladie du Québec, effective May 26, 2022. Vascepa will be reimbursed by RAMQ for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides. As disclosed previously, HLS has achieved reimbursement for Vascepa for more than 90% of privately covered lives in Canada for statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or due to diabetes, and at least one other cardiovascular risk factor.